Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10017570HBVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30010694HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052490HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052491HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052492HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052493HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TVIS30052494HIVENSG00000135914.6protein_codingHTR2BNoNo3357P41595
TCGA Plot Options
Drug Information
GeneHTR2B
DrugBank IDDB06216
Drug NameAsenapine
Target IDBE0000393
UniProt IDP41595
Regulation Typeantagonist
PubMed IDs21655346; 18308814
CitationsCitrome L: Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:325-39. doi: 10.2147/NDT.S16077. Epub 2011 May 26.@@Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28.
GroupsApproved
Direct Classification
SMILESCN1CC2C(C1)C1=C(OC3=CC=C(Cl)C=C23)C=CC=C1
Pathways
PharmGKB
ChEMBLCHEMBL3187365